Association between Fat Mass and Obesity Associated (FTO) gene polymorphism (rs9939609) and lipid profile in type 2 diabetic obese Iraqi male

Fadhil Jawad Al-Tu’ma,* and Khamail Hassan Obeda

*Department of Biochemistry, College of Medicine, University of Kerbala, Holy Kerbala, Iraq.
Correspondence to Fadhil Jawad Al-Tu’ma (email: f_altoma_56@yahoo.com).
Submitted: 26 September 2017 – Revised version received: 11 November 2017 – Accepted: 13 December 2017 – Published online: 26 March 2018

Objective Investigation the risk of allele frequency of FTO gene polymorphism rs9939609 in obese male with type 2 diabetes mellitus (T2DM) and to examine the association of this polymorphism of FTO gene with BMI and lipid profile in obese Iraqi male.

Methods The study included 120 patients (males) with T2DM and 60 healthy controls to explore the relation of these SNPs with T2DM in obese male in Iraqi population. The patient’s group was enrolled from Al-Husain medical city in Kerbala province based on WHO guidelines of T2DM. BMI, fasting blood sugar (FBS), lipid profile and HbA1c were measured, DNA was isolated from whole blood and the FTO gene variant (rs9939609) was genotyped by using ARMS–PCR technique with using specific primers. Multinomial logistic regression was applied to compare the proportions of genotypes or alleles. The odds ratio, t-test, and P-value at 95% confidence interval (CI) were measured before and after adjustment of BMI and age. Also in the present study, the Hardy Weinberg equilibrium was tested.

Results The results of our study showed there were no significant differences between the SNP rs9939609 in the FTO gene and T2DM in Iraqi obese male, and the genotyping results of rs9939609 was consistent with Hardy–Weinberg equilibrium in obese T2DM, non-obese T2DM, and control individuals (\(P = 0.05\), \(P = 0.46\) and \(P = 0.002\), respectively). The results show that the studied SNP of FTO gene have significant association with BMI and HDL-C level, but not have association with other parameters in obese diabetic patients group, while it is exhibited failure of FTO gene polymorphism to affect any of the measured clinical characteristics in non-obese diabetic patients.

Conclusions The FTO gene polymorphism rs9939609 have significant association with HDL-C level in obese diabetic Iraqi male but does not affect other tested biochemical parameters.

Keywords lipid profile, T2DM, fat mass and obesity-associated (FTO) gene, rs9939609

Introduction

Obesity has become a serious public health issue and increasingly prevalent in both developed and developing countries.1 The main adverse results of obesity are cardiovascular disease, type 2 diabetes and several cancers.2 Type 2 diabetes mellitus (T2DM) is the most common endocrine disease and one of the most acute medical and societal problems, as it lead to early disability and increased mortality from different complications.3,4 T2DM is a multifactorial disease; its pathogenesis is characterized by β-cell dysfunction accompanied by reduced insulin secretion and β-cell mass, a diminished incretin response, increased glucagon secretion, augmented liver glucose production, enhanced glucose reabsorption, activated lipolysis, reduced glucose absorption by the muscles and neurotransmitter dysfunctions.5

Several studies have shown significant association between adiposity, dyslipidemia, hypertension, diabetes mellitus or an increased cardiovascular risk and SNPs that have been previously found to influence plasma lipid levels and cardiovascular disease are APOA1 (rs670), APOA5 (rs662799), CETP (rs1800777), and FTO (rs9939609).6 These genes involved in the regulation of plasma lipid levels. Genetic variation and environmental factors are thought to contribute to the development of T2DM.3

The fat mass and obesity-associated FTO gene is recognized as associated with enhanced adiposity and appears to influence the risk of obesity in different nationalities.7,8 FTO gene is a polymorphic gene located on chromosome 16 at position 16q12.2. This gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase, which is involved in DNA repair and fatty acid metabolism. This gene is known as one of the most effective genes in human metabolic pathways with nearly 10,000 variations.9 The FTO protein catalyzes the demethylation of single-stranded nucleic acids. The FTO mRNA is abundant in many tissues, particularly in the hypothalamic nuclei controlling energy balance. Some researches indicate that the FTO gene plays a role in nervous and cardiovascular systems although its biological function is not fully known yet. It is suggested that catalytic activity of FTO may regulate the transcription of genes involved in fatty acid and glucose metabolism.10

The catalytic activity of FTO may regulate the transcription of genes involved in metabolism by nucleic acid demethylation. It was found that FTO-dependent demethylation of specific mRNAs in vivo relates to the control of the dopaminergic signaling pathway.11 The genetic associations of human population have shown strong and significant relations between the fat mass and obesity-associated gene (FTO) polymorphisms and obesity.12 However, limited studies are available on the effect of FTO variants on lipid concentrations in overweight and obese individuals,13,14 where find that loci associated with blood lipid levels are often associated with cardiovascular and metabolic traits, including coronary artery disease, T2DM, blood pressure, waist-hip ratio and body mass index (BMI).15 A meta-analysis of 17.037 white European individuals revealed associations between FTO variants not only with BMI, but also with fasting insulin, glucose, triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) concentrations.16 The influence of ethnic differences...
is often noted as the cause of these differences.15–17 Levels of low-density lipoprotein cholesterol (LDL-C), HDL-C, TG and total cholesterol (TC) areheritable, modifiable risk factors for coronary artery disease.11 The aim of this study was to investigate therisk allele frequency of FTO gene polymorphism rs9939609 in obese male with T2DM and to examine thereassociation of FTO gene polymorphism with BMI and lipid profile in obese Iraqi male.

Materials and Methods

Study subjects

A case-control study which including 180 males, 120 diabetic males and 60 healthy persons as control group, were conducted to assess the association of the (rs9939609) SNP of FTO gene with T2DM in obese males in Iraqi society.

Patients group

The patient samples included 120 obese subjects with T2DM divided into 60 obese type 2 diabetic patients and 60 non-obese type 2 diabetic patients were recruited from Al-Husain medical city, Karbala from January 2017 to December 2017. The cases and control subjects were recruited on the basis of following inclusion criteria: For cases: (a) patients those diagnosed by specialized physician as having T2DM according to WHO guidelines, (b) age of patients ≥35 years, (c) FBS > 126 mg/dl, (d) HbA1c > 6.5, (e) BMI > 30 Kg/m² for obese patients. The exclusion criteria were: (a) men those diagnosed with T1DM, (b) diabetic patients with age <35 years, (c) patients suffering from kidney or liver diseases, (d) patients with ischemic heart disease, (e) patients with tumor diseases, (f) patients who are taken lipid-lowering drugs such as statin.

Control group

The control group included 60 healthy persons were selected randomly from the general population who attend the hospital for checkup also from relatives and colleagues. The exclusion criteria for the control group were: (a) persons with (ischemic heart disease, acute or chronic kidney or liver diseases, or hypertension), (d) and persons who intake statin drug.

The inclusion criteria for non-diabetic controls were: (a) males with age at examination ≥35 years, (b) fasting blood glucose <100 mg/dl, (c) HbA1c values <6.0%, (d) no past medical history of type 2 diabetes, (e) no family history of type 2 diabetes in first and second degree relatives, (f) the range of BMI is 22 kg/m² < BMI < 36 kg/m², (g) TC <200 mg/dl, (h) and TG <150 mg/dl.

All subjects answer a detailed questionnaire that includes information about family history, the mean age was (35–79) years old, drug history, medical history and other relevant information, for all subjects’ weight, height and BMI had measured. All cases were collected from January 2017 to December 2017. It should be noted that Karbala was one of the big cities of Iraq, and there was no much difference in genotyping distribution from one city to another; therefore, our study society could represent the Iraqi society. Informed consent has been taken from all subjects. The study protocol was approved by Karbala Medical College Ethical Committee.

Phenotypic data

Height and body mass were used to calculate BMI. Plasma glucose, serum TG, HDL-C, LDL-C, VLDL-C and TC were determined from the blood.

Genotyping

The blood samples of T2DM and control groups were collected in EDTA-anticoagulated tubes, Genomic DNA was isolated from the whole blood by using the Genomic DNA mini kit (blood/cultured cell) (Gene aid/China). Then, DNA concentration and purity were measured by UV absorption at 260 and 280 nm (Nano-drop, USA).

Genotyping was carried out using tetra-primer amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) for FTO gene using the thermocycler (Cleaver, USA). The list of primers sequences and PCR condition used in our study for the SNP (rs9939609) of FTO gene obtained from Müller et al.18 as following:

- **Fout:** 5’-TGG CTC TTG AAT GAA ATA GGATTC AGA A-3’
- **Rout:** 5’-AGC CTC TCT ACC ATC TTA GTG CCA AAC A-3’
- **Fin:** 5’-TAG GTT CCT TGC GAC TGC TGT GAA TAT A-3’
- **Rin:** 5’-GAG TAA CAG AGA CTA TCC AAG TGC ATC TCA-3’

Amplification was performed in a 20 μl premix tube, each premix tube containing 0.7 μl from Fout and Rout outer primers which added, respectively, 1 μl from each inner primer, 5 μl of extracted DNA, and completed the volume to 20 μl by distilled water. Cycling conditions were 93°C for 5 min followed by 30 cycles of 93°C for 30 s, 53 cycles of 72°C for 25 s, and the final extension of 72°C for 5 min. Amplification product of FTO gene was 321 bp. Amplification product of FTO gene was run on 1.5% agarose gel.

Statistical analysis

Phenotypes data expressed as mean ± SD and genotypes data expressed as frequencies, ANOVA test and Student t-test used to compare phenotypes data between control group and obese and non-obese T2DM groups, and across genotypes using SPSS windows software (SPSS Inc., Chicago, IL). Association analysis of rs9939609 SNP with T2DM was performed using Pearson’s Chi-squared test. Multi-nominal logistic regression analysis was used to further test the association of SNP with T2DM measured by odds ratio (OR) and corresponding 95% confidence interval (CI) after adjusting for age and BMI as covariates. Association analysis was also performed assuming co-dominant, dominant and recessive models.

Results

The case-control study was conducted on a total of 120 clinically confirmed T2DM subjects (classified into 60 obese T2DM males and 60 non-obese T2DM males) and 60 healthy males as control group.
The clinical and biochemical characteristics of the study subjects were presented in (Table 1); it revealed significant differences in FBS, Age, HbA1c, BMI and lipid profile between obese T2DM group, non-obese T2DM group and control group.

**Genotyping**

Genotypes did not deviate from Hardy–Weinberg equilibrium in obese T2DM, non-obese T2DM and control individuals (P = 0.05), (P = 0.46) and (P = 0.002). respectively (Table 2).

PCR product of FTO gene polymorphism (rs9939609) was electrophoresed on 1.5% agarose (100 V and 90 min) and then stained with ethidium bromide, later visualized under UV light. Results discovered two bands (321, 210 bp) for TT wild type, three bands (321, 210, 178 bp) for AA homozygous and two bands (321, 178 bp) for TA heterozygous genotypes, as shown in Fig. 1.

The Genotype and allele frequencies of FTO gene variant are shown in Table 3. There is no statistically significant association was observed between genotypes of FTO gene variant rs9939609 and T2DM (Table 3).

The biochemical characteristics of studied individuals according to FTO gene variants rs9939609 show significant association between the studied SNP and BMI, HDL-C in obese diabetic group, while failure of FTO gene polymorphism to affect any of the measured clinical characteristics in non-obese diabetic group. (Tables 4 and 5).

**Discussion**

In this study, we observed that there are lipid abnormalities and significant correlations when compared between clinical and biochemical characteristics of the three groups obese T2DM, non-obese T2DM and control group with P-values (P < 0.05) in FBS, BMI, Age, HbA1c, TC, HDL-C, LDL-C and VLDL- C, but there is no significant association with TG (P > 0.05), this results inconsistent with the findings of Laith et al. and this abnormalities including, elevated TG, decrease HDL-C and increase VLDL-C in obese T2DM patients consistent with the findings of Hanish et al. Such results can be explained through the fact that individuals with type 2 diabetes have an increased prevalence of lipid profile abnormalities which contributes to higher rates of CAD. Such results coordinate with the findings of Al Taee.

For our knowledge, this is the first study to investigate the allele frequency and genotype distribution of FTO gene rs9939609 and its association with disturbances of serum lipids in Iraqi male population.

Biochemical characteristics (BMI, cholesterol, TG, VLDL-C, LDL-C and HDL-C) of T2DM obese patients were analyzed with respect to the distribution of the genotypes. Genotypes of the FTO gene were considered only due to the no significant changes of this SNP with respect to T2DM that were obtained.

Results of our study show significant association of BMI (P = 0.031), and HDL value (P = 0.04), but no significant association with other biochemical parameters (TC, TG, LDL-C and VLDL-C) in obese diabetic group with TT, TA and AA genotypes. This came in contrast with other studies which showed non-significant association with all lipid profiles or showed association with elevated TG levels. However, it came in agreement with other studies that reveal decrease HDL-C levels. Moreover, the associations in other studies were more common in men. Subjects with AA genotype have higher BMI compared to TA and TT carriers; however, this difference did not reach statistical significance, may be due to relatively small sample size and different effect size in case of BMI. This is in agreement with three previous studies that did not detect association of FTO polymorphism (rs9939609) with BMI in a similar sample size. On the other hand, other studies showed that FTO risk allele was associated with a significant increase in BMI (Ewens et al. 2011).

**Table 1. Clinical and biochemical characteristics of study subjects**

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Control subjects = 60</th>
<th>T2DM obese subjects = 60</th>
<th>T2DM non-obese subjects = 60</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS (mg/dl)</td>
<td>104.71 ± 17.99</td>
<td>249.85 ± 85.03</td>
<td>222.9 ± 81.54</td>
<td>0.001</td>
</tr>
<tr>
<td>Age (y)</td>
<td>49.37 ± 11.86</td>
<td>52.45 ± 9.92</td>
<td>55.38 ± 10.95</td>
<td>0.012</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.08 ± 3.89</td>
<td>31.42 ± 1.95</td>
<td>23.46 ± 1.18</td>
<td>0.001</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>184.81 ± 51.41</td>
<td>176.8 ± 36.87</td>
<td>164.64 ± 37.91</td>
<td>0.035</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>197.06 ± 94.94</td>
<td>229.95 ± 106.27</td>
<td>199.55 ± 93.05</td>
<td>0.127</td>
</tr>
<tr>
<td>VLDL-C (mg/dl)</td>
<td>38.48 ± 19.37</td>
<td>46.7 ± 20.30</td>
<td>39.4 ± 18.61</td>
<td>0.04</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>120.43 ± 42.10</td>
<td>104.45 ± 34.13</td>
<td>100.44 ± 40.65</td>
<td>0.014</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.17 ± 0.79</td>
<td>9.39 ± 1.89</td>
<td>8.95 ± 2.10</td>
<td>0.001</td>
</tr>
</tbody>
</table>

BMI, body mass index; HbA1c, glycated hemoglobin; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low density lipoprotein cholesterol. Data were expressed as mean ± SD.

**Table 2. Analysis of Hardy–Weinberg equilibrium**

<table>
<thead>
<tr>
<th>Subjects</th>
<th>X²</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obese T2DM</td>
<td>9.6</td>
<td>0.05</td>
</tr>
<tr>
<td>Non-obese T2DM</td>
<td>3.56</td>
<td>0.46</td>
</tr>
<tr>
<td>Control</td>
<td>16.9</td>
<td>0.002</td>
</tr>
</tbody>
</table>

For our knowledge, this is the first study to investigate the allele frequency and genotype distribution of FTO gene rs9939609 and its association with disturbances of serum lipids in Iraqi male population.

Biochemical characteristics (BMI, cholesterol, TG, VLDL-C, LDL-C and HDL-C) of T2DM obese patients were analyzed with respect to the distribution of the genotypes. Genotypes of the FTO gene were considered only due to the no significant changes of this SNP with respect to T2DM that were obtained.

Results of our study show significant association of BMI (P = 0.031), and HDL value (P = 0.04), but no significant association with other biochemical parameters (TC, TG, LDL-C and VLDL-C) in obese diabetic group with TT, TA and AA genotypes. This came in contrast with other studies which showed non-significant association with all lipid profiles or showed association with elevated TG levels. However, it came in agreement with other studies that reveal decrease HDL-C levels. Moreover, the associations in other studies were more common in men. Subjects with AA genotype have higher BMI compared to TA and TT carriers; however, this difference did not reach statistical significance, may be due to relatively small sample size and different effect size in case of BMI. This is in agreement with three previous studies that did not detect association of FTO polymorphism (rs9939609) with BMI in a similar sample size. On the other hand, other studies showed that FTO risk allele was associated with a significant increase in BMI (Ewens et al. 2011).

**Fig. 1** Product of FTO gene polymorphism (rs9939609) analyzed on 1.5% agarose gel electrophoresis.
In the present study, there were no significant differences between the three genotypes of FTO rs9939609 polymorphism in the BMI, blood glucose concentration and lipid profile. This result agreed with findings of other studies that appeared there is no significant association between FTO gene polymorphism with BMI, blood glucose concentration and lipid profile. The anti-atherogenic action of HDL results from its anti-inflammatory and antioxidant properties. Among the causes of lower HDL-C concentration were: overweight and obesity, physical inactivity, smoking, type 2 diabetes, elevated TGs concentration and genetic factors. The latter one is responsible for about 50% of the variability of HDL-C concentrations. Data from the United Kingdom Prospective Diabetes Study suggest that both reduced HDL-C and increased LDL-C predict CVD in diabetes mellitus (Sarat Chandra et al., 2014).

### Table 3. Genotype and allele frequency of rs9939609 polymorphism of FTO gene and association of this variant with T2DM in the study individuals

<table>
<thead>
<tr>
<th>Co-dominant</th>
<th>Control n = 60</th>
<th>Obese T2DM n = 60</th>
<th>Non-obese T2DM n = 60</th>
<th>Unadjusted OR (95% CI)</th>
<th>Adjusted OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT</td>
<td>25</td>
<td>32</td>
<td>28</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>TA</td>
<td>14</td>
<td>16</td>
<td>22</td>
<td>0.893 (0.367–2.16)</td>
<td>0.723 (0.317–2.36)</td>
</tr>
<tr>
<td>AA</td>
<td>21</td>
<td>12</td>
<td>10</td>
<td>0.446 (0.185–1.07)</td>
<td>0.521 (0.275–1.23)</td>
</tr>
</tbody>
</table>

**Dominant**

| AA + TA          | 35             | 28                | 32                    | 0.625 (0.30–1.28)      | 0.832 (0.42–1.34)     |

**Recessive**

| AA               | 21             | 12                | 10                    | 0.464 (0.203–1.06)     | 0.621 (0.324–1.22)    |

*For age and BMI.

### Table 4. Clinical characteristics of obese T2DM subjects according to FTO gene rs9939609 genotype

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>TT (n = 32)</th>
<th>TA (n = 16)</th>
<th>AA (n = 12)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>33.607 ± 2.266</td>
<td>31.85 ± 2.245</td>
<td>32.42 ± 2.314</td>
<td>0.031</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>172.3 ± 39.61</td>
<td>172.3 ± 35.14</td>
<td>197 ± 27.7</td>
<td>0.119</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>224.9 ± 113.6</td>
<td>221.6 ± 102.3</td>
<td>258.8 ± 98.64</td>
<td>0.60</td>
</tr>
<tr>
<td>VLDL-C (mg/dl)</td>
<td>46.85 ± 20.74</td>
<td>43.95 ± 20.49</td>
<td>51.54 ± 19.72</td>
<td>0.62</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>98.5 ± 38</td>
<td>107.9 ± 30.93</td>
<td>113 ± 29.28</td>
<td>0.40</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>32.93 ± 7.45</td>
<td>36.42 ± 11.59</td>
<td>41.67 ± 11.73</td>
<td>0.04</td>
</tr>
</tbody>
</table>

### Table 5. Clinical characteristics of non-obese T2DM subjects according to FTO gene rs9939609 genotype

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>TT (n = 28)</th>
<th>TA (n = 22)</th>
<th>AA (n = 10)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>23.535 ± 1.57</td>
<td>23.304 ± 7.64</td>
<td>23.66 ± 0.5</td>
<td>0.72</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>164.535 ± 44.854</td>
<td>162.91 ± 31.77</td>
<td>169.44 ± 31.68</td>
<td>0.86</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>184.428 ± 90.930</td>
<td>204.26 ± 85.126</td>
<td>234.55 ± 117.40</td>
<td>0.22</td>
</tr>
<tr>
<td>VLDL-C (mg/dl)</td>
<td>36.857 ± 17.456</td>
<td>39.652 ± 17.468</td>
<td>46.67 ± 23.34</td>
<td>0.22</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>97.248 ± 46.431</td>
<td>98.17 ± 32.19</td>
<td>116.22 ± 41.63</td>
<td>0.26</td>
</tr>
<tr>
<td>HDL-C (mg/dl)</td>
<td>37.035 ± 10.112</td>
<td>39.13 ± 13.44</td>
<td>32.44 ± 8.094</td>
<td>0.14</td>
</tr>
</tbody>
</table>
large group of Europeans. This association was also showed in studies on patients with abnormal glucose metabolism. A large meta-analysis confirmed the significant relation of the rs9939609 polymorphism with T2DM risk, where the frequency of distribution of rs9939609 among different ethnicities and its proposed association with BMI, insulin resistance and lipid profile. The limitation factors of this study could be relatively limited number of subjects in our groups and lack of matched control group due to cost and time limitation.

Conclusion

In conclusion, our findings suggest that FTO variant rs9939609 is not associated with the susceptibility of T2DM, but associated with obesity throw its effect on BMI. Our study also provides the evidence in support of the adipozy effect of this variant in HDL-C level in Iraqi obese male, and these results accordance with previous findings concerning an influence of FTO gene variants on HDL-C concentration. Further investigation on larger sample size is required.

References